<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LEVETIRACETAM- levetiracetam injection, solution, concentrate </strong><br>Sagent Pharmaceuticals<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Levetiracetam Injection safely and effectively. See full prescribing information for Levetiracetam Injection.<br>LEVETIRACETAM INJECTION, for intravenous use<br>Initial U.S. Approval: 1999
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="100%">
<col align="left" width="73.700%">
<col align="left" width="26.300%">
<tbody class="Headless">
<tr>
<td align="left" valign="top">Indications and Usage (<a href="#s3">1.1</a>, <a href="#s4">1.2</a>, <a href="#s5">1.3</a>)
</td>
<td align="right" valign="top">10/2014
</td>
</tr>
<tr>
<td align="left" valign="top">Dosage and Administration (<a href="#s7">2.1</a>, <a href="#s14">2.3</a>, <a href="#s19">2.6</a>)
</td>
<td align="right" valign="top">10/2014
</td>
</tr>
<tr>
<td align="left" valign="top">Warnings and Precautions (<a href="#s29">5.1</a>, <a href="#s32">5.2</a>, <a href="#s39">5.7</a>)
</td>
<td align="right" valign="top">10/2014
</td>
</tr>
<tr>
<td align="left" valign="top">Warnings and Precautions, Hematologic Abnormalities (<a href="#s38">5.6</a>)
</td>
<td align="right" valign="top">03/2015
</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Levetiracetam Injection is indicated for adjunctive therapy, as an alternative when oral administration is temporarily not feasible, in the treatment of:
 </p>
<ul class="Disc">
<li>Partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in patients 1 month of age and older with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (<a href="#s3">1.1</a>)
</li>
<li>Myoclonic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in patients 12 years of age and older with juvenile <span class="product-label-link" type="condition" conceptid="4290772" conceptname="Myoclonic seizure">myoclonic epilepsy</span> (<a href="#s4">1.2</a>)
</li>
<li>Primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span> in patients 6 years of age and older with idiopathic generalized <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (<a href="#s5">1.3</a>)
</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Levetiracetam Injection is for intravenous use only (<a href="#s7">2.1</a>)
 </p>
<p class="Highlighta"><span class="Underline">Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span> </p>
<ul class="Disc">
<li>1 Month to &lt;6 Months: 7 mg/kg twice daily; increase by 7 mg/kg twice daily every 2 weeks to recommended dose of 21 mg/kg twice daily (<a href="#s7">2.1</a>)
</li>
<li>6 Months to &lt;4 Years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 25 mg/kg twice daily (<a href="#s7">2.1</a>)
</li>
<li>4 Years to &lt;16 Years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily (<a href="#s7">2.1</a>)
</li>
<li>Adults 16 Years and Older: 500 mg twice daily; increase by 500 mg twice daily every 2 weeks to a recommended dose of 1,500 mg twice daily (<a href="#s7">2.1</a>)
</li>
</ul>
<p class="Highlighta"><span class="Underline">Myoclonic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> in Adults and Pediatric Patients 12 Years and Older</span> </p>
<ul class="Disc"><li>500 mg twice daily; increase by 500 mg twice daily every 2 weeks to recommended dose of 1,500 mg twice daily (<a href="#s13">2.2</a>)
</li></ul>
<p class="Highlighta"><span class="Underline">Primary Generalized Tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">Clonic Seizures</span></span> </p>
<ul class="Disc">
<li>6 Years to &lt; 16 Years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily (<a href="#s14">2.3</a>)
</li>
<li>Adults 16 Years and Older: 500 mg twice daily; increase by 500 mg twice daily every 2 weeks to recommended dose of 1,500 mg twice daily (<a href="#s14">2.3</a>)
</li>
</ul>
<p class="Highlighta"><span class="Underline">Switching From or To Oral Levetiracetam</span> </p>
<p class="Highlighta">When switching from oral levetiracetam, the initial total daily dosage/frequency of levetiracetam injection should be equivalent to those of oral levetiracetam.
 </p>
<p class="Highlighta">At the end of the intravenous treatment period, the patient may be switched to levetiracetam oral administration at the equivalent daily dosage and frequency (<a href="#s17">2.4</a>, <a href="#s18">2.5</a>)
 </p>
<p class="Highlighta">See full prescribing information for preparation and administration instructions (<a href="#s19">2.6</a>) and dosage adjustment in adult patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (<a href="#s22">2.7</a>)
 </p>
</div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Levetiracetam Injection: 500 mg per 5 mL Single-Dose Vial (<a href="#s26">3</a>)
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None (<a href="#s27">4</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Behavioral abnormalities including <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> symptoms, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, and <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> have been observed; monitor patients for psychiatric signs and symptoms (<a href="#s29">5.1</a>)
</li>
<li>Monitor for <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and advise patients not to drive or operate machinery until they have gained sufficient experience on levetiracetam (<a href="#s32">5.2</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="4218977" conceptname="Drug withdrawal seizure">Withdrawal Seizures</span>: Levetiracetam must be gradually withdrawn. (<a href="#s37">5.5</a>)
</li>
</ul></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div><div>
<div></div>
<div></div>
</div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence ≥ 5% more than placebo) include:
 </p>
<ul class="Disc">
<li>Adults: <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (<a href="#s42">6.1</a>)
</li>
<li>Pediatric patients: <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, and <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> (<a href="#s42">6.1</a>)
</li>
</ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals, Inc. at 1-866-625-1618 or FDA at 1-800-FDA-1088 or </span><span class="Bold Underline">www.fda.gov/medwatch</span><span class="Bold">.</span> </p>
</div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Pregnancy: Plasma levels of levetiracetam may be decreased and therefore need to be monitored closely during pregnancy. Based on animal data, may cause fetal harm (<a href="#s40">5.8</a>, <a href="#s53">8.1</a>)
 </p></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 3/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE
</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Myoclonic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> in Patients with Juvenile <span class="product-label-link" type="condition" conceptid="4290772" conceptname="Myoclonic seizure">Myoclonic Epilepsy</span>
</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Primary Generalized Tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">Clonic Seizures</span>
</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosing for Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosing for Myoclonic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> in Patients with Juvenile <span class="product-label-link" type="condition" conceptid="4290772" conceptname="Myoclonic seizure">Myoclonic Epilepsy</span>
</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Dosing for Primary Generalized Tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">Clonic Seizures</span>
</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Switching from Oral Dosing
</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Switching to Oral Dosing
</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Preparation and Administration Instructions
</a></h2>
<h2><a href="#section-2.7" class="toc">2.7 Dosage Adjustments in Adult Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h2><a href="#section-2.8" class="toc">2.8 Compatibility and Stability
</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Behavioral Abnormalities and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic</span> Symptoms
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Serious Dermatological Reactions
</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Coordination Difficulties
</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="4218977" conceptname="Drug withdrawal seizure">Withdrawal Seizures</span>
</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Hematologic Abnormalities
</a></h2>
<h2><a href="#section-5.7" class="toc"><span class="XmChange"></span>5.7 Increase in Blood Pressure
</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Control During Pregnancy
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience
</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience
</a></h2>
<h1><a href="#section-7" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-7.2" class="toc">8.2 Labor and Delivery
</a></h2>
<h2><a href="#section-7.3" class="toc">8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-7.4" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-7.5" class="toc">8.5 Geriatric Use
</a></h2>
<h2><a href="#section-7.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h1><a href="#section-8" class="toc">10 OVERDOSAGE
</a></h1>
<h2><a href="#section-8.1" class="toc">10.1 Signs, Symptoms and Laboratory Findings of Acute Overdosage in Humans
</a></h2>
<h2><a href="#section-8.2" class="toc">10.2 Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span>
</a></h2>
<h2><a href="#section-8.3" class="toc">10.3 Hemodialysis
</a></h2>
<h1><a href="#section-9" class="toc">11 DESCRIPTION
</a></h1>
<h1><a href="#section-10" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-10.1" class="toc">12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-10.2" class="toc">12.2 Pharmacodynamics
</a></h2>
<h2><a href="#section-10.3" class="toc">12.3  Pharmacokinetics
</a></h2>
<h1><a href="#section-11" class="toc">13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-11.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-12" class="toc">14 CLINICAL STUDIES
</a></h1>
<h2><a href="#section-12.1" class="toc">14.1 Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</a></h2>
<h2><a href="#section-12.2" class="toc">14.2 Myoclonic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> in Patients with Juvenile <span class="product-label-link" type="condition" conceptid="4290772" conceptname="Myoclonic seizure">Myoclonic Epilepsy</span>
</a></h2>
<h2><a href="#section-12.3" class="toc">14.3 Primary Generalized Tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">Clonic Seizures</span>
</a></h2>
<h1><a href="#section-13" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h2><a href="#section-13.1" class="toc">16.1 How Supplied
</a></h2>
<h2><a href="#section-13.2" class="toc">16.2 Storage
</a></h2>
<h1><a href="#section-14" class="toc">17 PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s2"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>Levetiracetam Injection is indicated as adjunctive therapy in the treatment of partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in adults and children 1 month of age and older with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>. Levetiracetam Injection is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Myoclonic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> in Patients with Juvenile <span class="product-label-link" type="condition" conceptid="4290772" conceptname="Myoclonic seizure">Myoclonic Epilepsy</span>
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>Levetiracetam Injection is indicated as adjunctive therapy in the treatment of myoclonic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in adults and adolescents 12 years of age and older with juvenile <span class="product-label-link" type="condition" conceptid="4290772" conceptname="Myoclonic seizure">myoclonic epilepsy</span>. Levetiracetam Injection is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Primary Generalized Tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">Clonic Seizures</span>
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>Levetiracetam Injection is indicated as adjunctive therapy in the treatment of primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span> in adults and children 6 years of age and older with idiopathic generalized <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>. Levetiracetam Injection is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s6"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosing for Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-2.1.1"></a><p></p>
<p class="First"><span class="Underline">Adults 16 Years and Older</span></p>
<p>Initiate treatment with a daily dose of 1,000 mg/day, given as twice-daily dosing (500 mg twice daily). Additional dosing increments may be given (1,000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3,000 mg. There is no evidence that doses greater than 3,000 mg/day confer additional benefit.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-2.1.2"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="Underline">Pediatric Patients</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-2.1.2.1"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="Italics">1 Month to &lt; 6 Months</span></p>
<p style="border-left:1px solid;"><span class="XmChange"></span> Initiate treatment with a daily dose of 14 mg/kg in 2 divided doses (7 mg/kg twice daily). Increase the daily dose every 2 weeks by increments of 14 mg/kg to the recommended daily dose of 42 mg/kg (21 mg/kg twice daily). In the clinical trial, the mean daily dose was 35 mg/kg in this age group. The effectiveness of lower doses has not been studied.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-2.1.2.2"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="Italics">6 Months to &lt; 4 Years</span></p>
<p style="border-left:1px solid;"><span class="XmChange"></span> Initiate treatment with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). Increase the daily dose every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 50 mg/kg (25 mg/kg twice daily). If a patient cannot tolerate a daily dose of 50 mg/kg, the daily dose may be reduced. In the clinical trial, the mean daily dose was 47 mg/kg in this age group.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-2.1.2.3"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="Italics">4 Years to &lt; 16 Years</span></p>
<p style="border-left:1px solid;"><span class="XmChange"></span> Initiate treatment with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). Increase the daily dose every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical trial, the mean daily dose was 44 mg/kg. The maximum daily dose was 3,000 mg/day.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dosing for Myoclonic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> in Patients with Juvenile <span class="product-label-link" type="condition" conceptid="4290772" conceptname="Myoclonic seizure">Myoclonic Epilepsy</span>
</h2>
<p class="First">Initiate treatment with a dose of 1,000 mg/day, given as twice-daily dosing (500 mg twice daily). Increase the dosage by 1,000 mg/day every 2 weeks to the recommended daily dose of 3,000 mg. The effectiveness of doses lower than 3,000 mg/day has not been studied.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Dosing for Primary Generalized Tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">Clonic Seizures</span>
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-2.3.1"></a><p></p>
<p class="First"><span class="Underline">Adults 16 Years and Older</span></p>
<p>Initiate treatment with a dose of 1,000 mg/day, given as twice-daily dosing (500 mg twice daily). Increase dosage by 1,000 mg/day every 2 weeks to the recommended daily dose of 3,000 mg. The effectiveness of doses lower than 3,000 mg/day has not been adequately studied.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-2.3.2"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="Underline">Pediatric Patients Ages 6 to &lt;16 Years</span></p>
<p style="border-left:1px solid;"><span class="XmChange"></span>Initiate treatment with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). Increase the daily dose every 2 weeks by increments of 20 mg/kg (10 mg/kg twice daily) to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). The effectiveness of doses lower than 60 mg/kg/day has not been adequately studied.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Switching from Oral Dosing
</h2>
<p class="First">When switching from oral levetiracetam, the initial total daily intravenous dosage of levetiracetam should be equivalent to the total daily dosage and frequency of oral levetiracetam.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Switching to Oral Dosing
</h2>
<p class="First">At the end of the intravenous treatment period, the patient may be switched to levetiracetam oral administration at the equivalent daily dosage and frequency of the intravenous administration.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Preparation and Administration Instructions
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>Levetiracetam injection is for intravenous use only and should be diluted in 100 mL of a compatible diluent prior to administration. If a smaller volume is required (e.g. pediatric patients), the amount of diluent should be calculated to not exceed a maximum levetiracetam concentration of 15 mg per mL of diluted solution. Consideration should also be given to the total daily fluid intake of the patient. Levetiracetam injection should be administered as a 15-minute IV infusion. One vial of levetiracetam injection contains 500 mg levetiracetam (500 mg per 5 mL).
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Product with particulate matter or discoloration should not be used.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>Any unused portion of the levetiracetam injection vial contents should be discarded.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-2.6.1"></a><p></p>
<p class="First"><span class="Underline">Adults</span></p>
<p>See <a href="#t1">Table 1</a> for the recommended preparation and administration of levetiracetam injection for adults to achieve a dose of 500 mg, 1,000 mg, or 1,500 mg.
</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1: Preparation and Administration of Levetiracetam Injection for Adults
</span></caption>
<col align="left" width="17.850%">
<col align="left" width="33.925%">
<col align="left" width="25.000%">
<col align="left" width="23.225%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Dose</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Withdraw Volume</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Volume of Diluent</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Infusion Time</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">500 mg
</td>
<td class="Botrule Rrule" align="center" valign="top">5 mL (5 mL vial)
</td>
<td class="Botrule Rrule" align="center" valign="top">100 mL
</td>
<td class="Botrule Rrule" align="center" valign="top">15 minutes
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">1,000 mg
</td>
<td class="Botrule Rrule" align="center" valign="top">10 mL (two 5 mL vials)
</td>
<td class="Botrule Rrule" align="center" valign="top">100 mL
</td>
<td class="Botrule Rrule" align="center" valign="top">15 minutes
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">1,500 mg
</td>
<td class="Botrule Rrule" align="center" valign="top">15 mL (three 5 mL vials)
</td>
<td class="Botrule Rrule" align="center" valign="top">100 mL
</td>
<td class="Botrule Rrule" align="center" valign="top">15 minutes
</td>
</tr>
</tbody>
</table>
<p>For example, to prepare a 1,000 mg dose, dilute 10 mL of levetiracetam injection in 100 mL of a compatible diluent and administer intravenously as a 15-minute infusion.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-2.6.2"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="Underline">Pediatric Patients</span></p>
<p style="border-left:1px solid;"><span class="XmChange"></span>When using levetiracetam injection for pediatric patients, dosing is weight-based (mg per kg).
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>The following calculation should be used to determine the appropriate daily dose of levetiracetam injection for pediatric patients:
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>                                                   Daily dose (mg/kg/day) x patient weight (kg)<br>Total daily dose (mL/day) = ---------------------------------------------<br>                                                                         100 mg/mL
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-2.7"></a><p></p>
<h2>2.7 Dosage Adjustments in Adult Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">Levetiracetam dosing must be individualized according to the patient's renal function status. Recommended dosage adjustments for adults with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> are shown in <a href="#t2">Table 2</a>. Information is unavailable for dosage adjustments in pediatric patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. In order to calculate the dose recommended for adult patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, creatinine clearance adjusted for body surface area must be calculated. To do this an estimate of the patient's creatinine clearance (CLcr) in mL/min must first be calculated using the following formula:
</p>
<p>                  [140-age (years)] x weight (kg)                           (x 0.85 for<br>CLcr=  - - - - - - - - - - - - - - - - - - - - - - - -                        female<br>                  72 x serum creatinine (mg/dL)                               patients)
</p>
<p>Then CLcr is adjusted for body surface area (BSA) as follows:
</p>
<p>                                             CLcr (mL/min)<br>CLcr (mL/min/1.73m<span class="Sup">2</span>)= - - - - - - - - - - - - - -  x 1.73<br>                                             BSA subject (m<span class="Sup">2</span>)
</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2: Dosage Adjustment Regimen for Adult Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</span></caption>
<col align="left" width="27.082%">
<col align="left" width="24.306%">
<col align="left" width="24.306%">
<col align="left" width="24.306%">
<tfoot><tr class="First Last"><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Sup">1</span>Following dialysis, a 250 to 500 mg supplemental dose is recommended.
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Group
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">Creatinine Clearance<br>(mL/min/1.73m<span class="Sup">2</span>)
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">Dosage<br>(mg)
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">Frequency
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Normal
</td>
<td class="Botrule Rrule" align="center" valign="top">&gt; 80
</td>
<td class="Botrule Rrule" align="center" valign="top">500 to 1,500
</td>
<td class="Botrule Rrule" align="center" valign="top">Every 12 hours
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Mild
</td>
<td class="Botrule Rrule" align="center" valign="top">50 to 80
</td>
<td class="Botrule Rrule" align="center" valign="top">500 to 1,000
</td>
<td class="Botrule Rrule" align="center" valign="top">Every 12 hours
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Moderate
</td>
<td class="Botrule Rrule" align="center" valign="top">30 to 50
</td>
<td class="Botrule Rrule" align="center" valign="top">250 to 750
</td>
<td class="Botrule Rrule" align="center" valign="top">Every 12 hours
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Severe
</td>
<td class="Botrule Rrule" align="center" valign="top">&lt; 30
</td>
<td class="Botrule Rrule" align="center" valign="top">250 to 500
</td>
<td class="Botrule Rrule" align="center" valign="top">Every 12 hours
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">ESRD patients using dialysis
</td>
<td class="Botrule Rrule" align="center" valign="top">-------
</td>
<td class="Botrule Rrule" align="center" valign="top">500 to 1,000<span class="Sup">1</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Every 24 hours<span class="Sup">1</span>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-2.8"></a><p></p>
<h2>2.8 Compatibility and Stability
</h2>
<p class="First">Levetiracetam injection was found to be physically compatible and chemically stable when mixed with the following diluents and antiepileptic drugs for at least 24 hours and stored in polyvinyl chloride (PVC) bags at controlled room temperature 15° to 30°C (59° to 86°F).
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-2.8.1"></a><p></p>
<p class="First"><span class="Underline">Diluents</span></p>
<p>Sodium chloride (0.9%) injection, USP
</p>
<p>Lactated Ringer's injection
</p>
<p>Dextrose 5% injection, USP
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-2.8.2"></a><p></p>
<p class="First"><span class="Underline">Other Antiepileptic Drugs</span></p>
<p>Lorazepam
</p>
<p>Diazepam
</p>
<p>Valproate sodium
</p>
<p>There is no data to support the physical compatibility of levetiracetam injection with antiepileptic drugs that are not listed above.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s26"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">One vial of Levetiracetam Injection contains 500 mg levetiracetam (500 mg per 5 mL).
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s27"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS
</h1>
<p class="First">None.
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s28"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Behavioral Abnormalities and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic</span> Symptoms
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>Levetiracetam may cause behavioral abnormalities and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> symptoms. Patients treated with levetiracetam should be monitored for psychiatric signs and symptoms.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-5.1.1"></a><p></p>
<p class="First"><span class="Underline">Behavioral abnormalities</span></p>
<p style="border-left:1px solid;"><span class="XmChange"></span>In clinical studies using an oral formulation of levetiracetam, 13% of adult levetiracetam-treated patients and 38% of pediatric levetiracetam-treated patients (4 to 16 years of age), compared to 6% and 19% of adult and pediatric placebo-treated patients, experienced non-<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> behavioral symptoms (reported as <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4327815" conceptname="Feeling angry">anger</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="444243" conceptname="Neurosis">neurosis</span>, and <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">personality disorder</span>).
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>A randomized, double-blind, placebo-controlled study was performed to assess the neurocognitive and behavioral effects of an oral formulation of levetiracetam as adjunctive therapy in pediatric patients (4 to 16 years of age). The results from an exploratory analysis indicated a worsening in levetiracetam-treated patients on <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> (one of eight behavior dimensions), as measured in a standardized and systematic way using a validated instrument, the Achenbach Child Behavior Checklist (CBCL/6-18).
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>In clinical studies in pediatric patients 1 month to &lt; 4 years of age, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> was reported in 12% of the levetiracetam-treated patients compared to 0% of placebo-treated patients.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>In clinical studies, 1.7% of adult levetiracetam-treated patients discontinued treatment due to behavioral adverse reactions, compared to 0.2% of placebo-treated patients. The treatment dose was reduced in 0.8% of adult levetiracetam-treated patients and in 0.5% of placebo-treated patients. Overall, 11% of levetiracetam-treated pediatric patients experienced behavioral symptoms associated with discontinuation or dose reduction, compared to 6% of placebo-treated patients.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-5.1.2"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="Underline"><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic</span> symptoms</span></p>
<p style="border-left:1px solid;"><span class="XmChange"></span>In clinical studies using an oral formulation of levetiracetam, 1% of levetiracetam-treated adult patients, 2% of levetiracetam-treated pediatric patients 4 to 16 years of age, and 17% of levetiracetam-treated pediatric patients 1 month to &lt;4 years of age experienced <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> symptoms, compared to 0.2%, 2%, and 5% in the corresponding age groups treated with placebo. In a controlled study that assessed the neurocognitive and behavioral effects of an oral formulation of levetiracetam in pediatric patients 4 to 16 years of age, 1.6% of levetiracetam-treated patients experienced <span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span>, compared to 0% of placebo-treated patients. In the same study, 3.1% of levetiracetam-treated patients experienced <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>, compared to 0% of placebo-treated patients <span class="Italics">[see Use in Specific Populations (<a href="#s58">8.4</a>)]</span>.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>In clinical studies, two (0.3%) levetiracetam-treated adult patients were hospitalized, and their treatment was discontinued due to <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. Both events, reported as <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, developed within the first week of treatment and resolved within 1 to 2 weeks following treatment discontinuation. There was no difference between drug- and placebo-treated patients in the incidence of the pediatric patients who discontinued treatment due to <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> and non-<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> adverse reactions.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>Levetiracetam may cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>. Patients should be monitored for <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and be advised not to drive or operate machinery until they have gained sufficient experience on levetiracetam to gauge whether it adversely affects their ability to drive or operate machinery.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-5.2.1"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="Underline"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></span></p>
<p>In controlled clinical studies using an oral formulation of levetiracetam in adult patients with partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, 15% of levetiracetam-treated patients reported <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, compared to 8% of placebo-treated patients. There was no clear dose response up to 3,000 mg/day. In a study in which there was no titration, about 45% of patients receiving levetiracetam 4,000 mg/day reported <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>. The <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> was considered serious in 0.3% of levetiracetam-treated patients, compared to 0% in the placebo group. About 3% of levetiracetam-treated patients discontinued treatment due to <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, compared to 0.7% of placebo-treated patients. In 1.4% of levetiracetam-treated patients and 0.9% of placebo-treated patients, the dose was reduced, while 0.3% of the levetiracetam-treated patients were hospitalized due to <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-5.2.2"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></span></p>
<p>In controlled clinical studies using an oral formulation of levetiracetam in adult patients with partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, 15% of levetiracetam-treated patients reported <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, compared to 9% of placebo-treated patients. Treatment was discontinued due to <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> in 0.8% of levetiracetam-treated patients as compared to 0.5% of placebo-treated patients. In 0.5% of levetiracetam-treated patients and in 0.2% of placebo-treated patients, the dose was reduced due to <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>.
</p>
<p><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> occurred most frequently within the first 4 weeks of treatment. In general, the incidences of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> in the pediatric partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> studies, and in pediatric and adult myoclonic and primary generalized tonic-clonic studies were comparable to those of the adult partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> studies.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Serious Dermatological Reactions
</h2>
<p class="First">Serious dermatological reactions, including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> (SJS) and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), have been reported in both pediatric and adult patients treated with levetiracetam. The median time of onset is reported to be 14 to 17 days, but cases have been reported at least four months after initiation of treatment. Recurrence of the serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> following rechallenge with levetiracetam has also been reported. Levetiracetam should be discontinued at the first sign of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, unless the <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this drug should not be resumed and alternative therapy should be considered.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Coordination Difficulties
</h2>
<p class="First">Levetiracetam may cause coordination difficulties. 
</p>
<p>In controlled clinical studies using an oral formulation of levetiracetam in adult patients with partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, 3.4% of levetiracetam-treated patients experienced coordination difficulties, (reported as <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span>, or <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>) compared to 1.6% of placebo-treated patients. A total of 0.4% of patients in controlled clinical studies discontinued levetiracetam treatment due to <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, compared to 0% of placebo-treated patients. In 0.7% of levetiracetam-treated patients and in 0.2% of placebo-treated patients, the dose was reduced due to coordination difficulties, while one of the treated patients was hospitalized due to worsening of pre-existing <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>. These events occurred most frequently within the first 4 weeks of treatment.
</p>
<p>Patients should be monitored for signs and symptoms of coordination difficulties and advised not to drive or operate machinery until they have gained sufficient experience on levetiracetam to gauge whether it could adversely affect their ability to drive or operate machinery.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="4218977" conceptname="Drug withdrawal seizure">Withdrawal Seizures</span>
</h2>
<p class="First">Antiepileptic drugs, including levetiracetam, should be withdrawn gradually to minimize the potential of increased <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s38"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Hematologic Abnormalities
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>Levetiracetam can cause hematologic abnormalities. Hematologic abnormalities occurred in clinical trials and included decreases in red blood cells count (RBC), hemoglobin, and hematocrit, and increases in eosinophil counts. Decreased white blood cells count (WBC) and neutrophil counts also occurred in clinical trials. Cases of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> have been reported in the postmarketing setting.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="e38"></a><a name="section-5.6.1"></a><p></p>
<p class="First"><span class="Underline">Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="e39"></a><a name="section-5.6.1.1"></a><p></p>
<p class="First"><span class="Italics">Adults</span></p>
<p>In controlled clinical studies using an oral formulation of levetiracetam in adult patients with partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, minor but statistically significant decreases compared to placebo in total mean RBC (0.03 x 10<span class="Sup">6</span>/mm<span class="Sup">3</span>), mean hemoglobin (0.09 g/dL), and mean hematocrit (0.38%), were seen in levetiracetam-treated patients.
</p>
<p>A total of 3.2% of levetiracetam-treated and 1.8% of placebo-treated patients had at least one possibly significant (≤2.8 x 10<span class="Sup">9</span>/L) decreased WBC, and 2.4% of levetiracetam-treated and 1.4% of placebo-treated patients had at least one possibly significant (≤1.0 x 10<span class="Sup">9</span>/L) decreased neutrophil count. Of the levetiracetam-treated patients with a low neutrophil count, all but one rose towards or to baseline with continued treatment. No patient was discontinued secondary to low neutrophil counts.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e40"></a><a name="section-5.6.1.2"></a><p></p>
<p class="First"><span class="Italics">Pediatric Patients 4 Years to &lt; 16 Years</span></p>
<p style="border-left:1px solid;"><span class="XmChange"></span>In a controlled study in pediatric patients age 4 years to &lt;16 years, statistically significant decreases in WBC and neutrophil counts were seen in levetiracetam-treated patients, as compared to placebo. The mean decreases from baseline in the levetiracetam-treated group were -0.4 x 10<span class="Sup">9</span>/L and -0.3 x 10<span class="Sup">9</span>/L, respectively, whereas there were small increases in the placebo group. Mean relative lymphocyte counts increased by 1.7% in levetiracetam-treated patients, compared to a decrease of 4% in placebo-treated patients (statistically significant).
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>More levetiracetam-treated patients had a possibly clinically significant abnormally low WBC value (3% of levetiracetam-treated patients versus 0% of placebo-treated patients); however, there was no apparent difference between treatment groups with respect to neutrophil count (5% on levetiracetam versus 4.2% on placebo). No patient was discontinued because of low WBC or neutrophil count.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>In a randomized, double-blind, placebo-controlled study to assess the neurocognitive and behavioral effects of an oral formulation of levetiracetam as adjunctive therapy in pediatric patients (4 to 16 years of age), 5 patients (8.6%) in the levetiracetam-treated group and two patients (6.1%) in the placebo-treated group had high eosinophil count values that were possibly clinically significant (≥10% or ≥0.7 x 10<span class="Sup">9</span>/L).
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s39"></a><a name="section-5.7"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange"></span>5.7 Increase in Blood Pressure
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>In a randomized, placebo-controlled study in patients 1 month to &lt;4 years of age using an oral formulation of levetiracetam, a significantly higher risk of increased diastolic blood pressure was observed in the levetiracetam-treated patients (17%), compared to placebo-treated patients (2%). There was no overall difference in mean diastolic blood pressure between the treatment groups. This disparity between the levetiracetam and placebo treatment groups was not observed in the studies of older children or in adults.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>Monitor patients 1 month to &lt;4 years of age for increases in diastolic blood pressure.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Control During Pregnancy
</h2>
<p class="First">Physiological changes may gradually decrease plasma levels of levetiracetam throughout pregnancy. This decrease is more pronounced during the third trimester. It is recommended that patients be monitored carefully during pregnancy. Close monitoring should continue through the postpartum period especially if the dose was changed during pregnancy.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s41"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<p class="First">The following adverse reactions are discussed in more details in other sections of labeling:
</p>
<ul class="Disc">
<li>Behavioral Abnormalities and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic</span> Symptoms <span class="Italics">[see Warnings and Precautions (<a href="#s29">5.1</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> <span class="Italics">[see Warnings and Precautions (<a href="#s32">5.2</a>)]</span>
</li>
<li>Serious Dermatological Reactions <span class="Italics">[see Warnings and Precautions (<a href="#s35">5.3</a>)]</span>
</li>
<li>Coordination Difficulties <span class="Italics">[see Warnings and Precautions (<a href="#s36">5.4</a>)]</span>
</li>
<li>Hematologic Abnormalities <span class="Italics">[see Warnings and Precautions (<a href="#s38">5.6</a>)]</span>
</li>
<li>Increase in Blood Pressure <span class="Italics">[see Warnings and Precautions (<a href="#s39">5.7</a>)]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="s42"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience
</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
</p>
<p>The adverse reactions that result from levetiracetam injection use include all of those reported for levetiracetam tablets and oral solution. Equivalent doses of intravenous (IV) levetiracetam and oral levetiracetam result in equivalent C<span class="Sub">max</span>, C<span class="Sub">min</span>, and total systemic exposure to levetiracetam when the IV levetiracetam is administered as a 15-minute infusion.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s43"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Underline">Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-6.1.1.1"></a><p></p>
<p class="First"><span class="Italics">Adults</span></p>
<p>In controlled clinical studies using levetiracetam tablets in adults with partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, the most common adverse reactions in adult patients receiving levetiracetam in combination with other AEDs, for events with rates greater than placebo, were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. Of the most common adverse reactions in adults experiencing partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> occurred predominantly during the first 4 weeks of treatment with levetiracetam.
</p>
<p><a href="#t3">Table 3</a> lists adverse reactions that occurred in at least 1% of adult <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> patients receiving levetiracetam tablets in placebo-controlled studies and were numerically more common than in patients treated with placebo. In these studies, either levetiracetam or placebo was added to concurrent AED therapy. 
</p>
<a name="t3"></a><table width="100%">
<caption><span>Table 3: Adverse Reactions* in Pooled Placebo-Controlled, Add-On Studies in Adults Experiencing Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</span></caption>
<col align="left" width="35.700%">
<col align="left" width="33.933%">
<col align="left" width="30.367%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Bold">*</span>Adverse reactions occurred in at least 1% of levetiracetam-treated patients and occurred more frequently than placebo-treated patients
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Levetiracetam</span><br><span class="Bold">(N=769)</span><br><span class="Bold">%</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">(N=439)</span><br><span class="Bold">%</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">15
</td>
<td class="Botrule Rrule" align="center" valign="top">9
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">15
</td>
<td class="Botrule Rrule" align="center" valign="top">8
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">14
</td>
<td class="Botrule Rrule" align="center" valign="top">13
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">13
</td>
<td class="Botrule Rrule" align="center" valign="top">8
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">9
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">7
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough Increased</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">Diplopia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Emotional Lability</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">Hostility</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
</tbody>
</table>
<p>In controlled adult clinical studies using levetiracetam tablets, 15% of patients receiving levetiracetam and 12% receiving placebo either discontinued or had a dose reduction as a result of an adverse reaction. <a href="#t4">Table 4</a> lists the most common (&gt;1%) adverse reactions that resulted in discontinuation or dose reduction and that occurred more frequently in levetiracetam-treated patients than in placebo-treated patients.
</p>
<a name="t4"></a><table width="100%">
<caption><span>Table 4: Adverse Reactions that Resulted in Discontinuation or Dose Reduction in Pooled Placebo-Controlled Studies in Adults Experiencing Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</span></caption>
<col align="left" width="36.433%">
<col align="left" width="36.433%">
<col align="left" width="27.133%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Levetiracetam</span><br><span class="Bold">(N=769)</span><br><span class="Bold">%</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">(N=439)</span><br><span class="Bold">%</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-6.1.1.2"></a><p></p>
<p class="First"><span class="Italics">Pediatric Patients 4 Years to &lt;16 Years</span></p>
<p>The adverse reaction data presented below was obtained from a pooled analysis of two controlled pediatric clinical studies using an oral formulation in pediatric patients 4 to 16 years of age with partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. The most common adverse reactions in pediatric patients receiving levetiracetam in combination with other AEDs, for events with rates greater than placebo, were <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, and <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>.
</p>
<p><a href="#t5">Table 5</a> lists adverse reactions from the pooled pediatric controlled studies (4 to 16 years of age) that occurred in at least 2% of pediatric levetiracetam-treated patients and were numerically more common than in pediatric patients treated with placebo. In these studies, either levetiracetam or placebo was added to concurrent AED therapy.
</p>
<a name="t5"></a><table width="100%">
<caption><span>Table 5: Adverse Reactions* in Pooled Placebo-Controlled, Add-On Studies in Pediatric Patients Ages 4 to 16 Years Experiencing Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</span></caption>
<col align="left" width="38.900%">
<col align="left" width="33.633%">
<col align="left" width="27.467%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Bold">*</span> Adverse reactions occurred in at least 2% of pediatric levetiracetam-treated patients and occurred more frequently than placebo-treated patients
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Levetiracetam</span><br><span class="Bold">(N=165)</span><br><span class="Bold">%</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">(N=131)</span><br><span class="Bold">%</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">19
</td>
<td class="Botrule Rrule" align="center" valign="top">15
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">15
</td>
<td class="Botrule Rrule" align="center" valign="top">12
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">15
</td>
<td class="Botrule Rrule" align="center" valign="top">12
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">13
</td>
<td class="Botrule Rrule" align="center" valign="top">9
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">11
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggression</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">10
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal Pain Upper</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">9
</td>
<td class="Botrule Rrule" align="center" valign="top">8
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">9
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal Congestion</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">9
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased Appetite</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">8
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       Abnormal Behavior
</td>
<td class="Botrule Rrule" align="center" valign="top">7
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">7
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">7
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       Pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">7
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Contusion</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Fall</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Mood Altered</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4197184" conceptname="Pseudobulbar affect">Affect Lability</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusional State</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">Ear Pain</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">Gastroenteritis</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="30234" conceptname="Neck sprain">Joint Sprain</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Mood Swings</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">Neck Pain</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">       Sedation
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
</tbody>
</table>
<p>In the controlled pooled pediatric clinical studies in patients 4 to 16 years of age, 7% of patients receiving levetiracetam and 9% receiving placebo discontinued as a result of an adverse reaction.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-6.1.1.3"></a><p></p>
<p class="First"><span class="Italics">Pediatric Patients 1 Month to &lt; 4 Years</span></p>
<p>In the 7-day controlled pediatric clinical study using an oral formulation of levetiracetam in children 1 month to less than 4 years of age with partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, the most common adverse reactions in patients receiving levetiracetam in combination with other AEDs, for events with rates greater than placebo, were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>. Because of the shorter exposure period, incidences of adverse reactions are expected to be lower than in other pediatric studies in older patients. Therefore, other controlled pediatric data, presented above, should also be considered to apply to this age group.
</p>
<p><a href="#t6">Table 6</a> lists adverse reactions that occurred in at least 5% of pediatric <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> patients (ages 1 month to &lt; 4 years) treated with levetiracetam in the placebo-controlled study and were numerically more common than in patients treated with placebo. In this study, either levetiracetam or placebo was added to concurrent AED therapy.
</p>
<a name="t6"></a><table width="100%">
<caption><span>Table 6: Adverse Reactions* in a Placebo-Controlled, Add-On Study in Pediatric Patients Ages 1 Month to &lt; 4 Years Experiencing Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</span></caption>
<col align="left" width="33.333%">
<col align="left" width="33.333%">
<col align="left" width="33.333%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Bold">*</span> Adverse reactions occurred in at least 5% of levetiracetam-treated patients and occurred more frequently than placebo-treated patients
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Levetiracetam</span><br><span class="Bold">(N=60)</span><br><span class="Bold">%</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">(N=56)</span><br><span class="Bold">%</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">13
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">12
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
</tbody>
</table>
<p>In the 7-day controlled pediatric clinical study in patients 1 month to &lt; 4 years of age, 3% of patients receiving levetiracetam and 2% receiving placebo either discontinued or had a dose reduction as a result of an adverse reaction. There was no adverse reaction that resulted in discontinuation for more than one patient.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Underline">Myoclonic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span></p>
<p>Although the pattern of adverse reactions in this study seems somewhat different from that seen in patients with <span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">partial seizures</span>, this is likely due to the much smaller number of patients in this study compared to partial <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> studies. The adverse reaction pattern for patients with JME is expected to be essentially the same as for patients with <span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">partial seizures</span>.
</p>
<p>In the controlled clinical study using levetiracetam tablets in patients with myoclonic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, the most common adverse reactions in patients receiving levetiracetam in combination with other AEDs, for events with rates greater than placebo, were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>, and <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>.
</p>
<p><a href="#t7">Table 7</a> lists adverse reactions that occurred in at least 5% of juvenile <span class="product-label-link" type="condition" conceptid="4290772" conceptname="Myoclonic seizure">myoclonic epilepsy</span> patients experiencing myoclonic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> treated with levetiracetam tablets and were numerically more common than in patients treated with placebo. In this study, either levetiracetam or placebo was added to concurrent AED therapy.
</p>
<a name="t7"></a><table width="100%">
<caption><span>Table 7: Adverse Reactions* in a Placebo-Controlled, Add-On Study in Patients 12 Years of Age and Older with Myoclonic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</span></caption>
<col align="left" width="41.067%">
<col align="left" width="32.133%">
<col align="left" width="26.800%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Bold">*</span> Adverse reactions occurred in at least 5% of levetiracetam-treated patients and occurred more frequently than placebo-treated patients
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Levetiracetam</span><br><span class="Bold">(N=60)</span><br><span class="Bold">%</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">(N=60)</span><br><span class="Bold">%</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">12
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">Neck pain</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">8
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">7
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
</tr>
</tbody>
</table>
<p>In the placebo-controlled study using levetiracetam tablets in patients with JME, 8% of patients receiving levetiracetam and 2% receiving placebo either discontinued or had a dose reduction as a result of an adverse reaction. The adverse reactions that led to discontinuation or dose reduction and that occurred more frequently in levetiracetam-treated patients than in placebo-treated patients are presented in <a href="#t8">Table 8</a>.
</p>
<a name="t8"></a><table width="100%">
<caption><span>Table 8: Adverse Reactions that Resulted in Discontinuation or Dose Reduction in Patients with Juvenile <span class="product-label-link" type="condition" conceptid="4290772" conceptname="Myoclonic seizure">Myoclonic Epilepsy</span>
</span></caption>
<col align="left" width="36.433%">
<col align="left" width="36.433%">
<col align="left" width="27.133%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Levetiracetam</span><br><span class="Bold">(N=60)</span><br><span class="Bold">%</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">(N=60)</span><br><span class="Bold">%</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="40546087" conceptname="Depressed mood">Depressed mood</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">Diplopia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="438134" conceptname="Hypersomnia">Hypersomnia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s48"></a><a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Underline">Primary Generalized Tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">Clonic Seizures</span></span></p>
<p>Although the pattern of adverse reactions in this study seems somewhat different from that seen in patients with <span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">partial seizures</span>, this is likely due to the much smaller number of patients in this study compared to partial <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> studies. The adverse reaction pattern for patients with primary generalized tonic-clonic (PGTC) <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> is expected to be essentially the same as for patients with <span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">partial seizures</span>.
</p>
<p>In the controlled clinical study that included patients 4 years of age and older with PGTC <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, the most common adverse reaction in patients receiving levetiracetam oral formulation in combination with other AEDs, for events with rates greater than placebo was <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>.
</p>
<p><a href="#t9">Table 9</a> lists adverse reactions that occurred in at least 5% of idiopathic generalized <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> patients experiencing PGTC <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> treated with levetiracetam and were numerically more common than in patients treated with placebo. In this study, either levetiracetam or placebo was added to concurrent AED therapy.
</p>
<a name="t9"></a><table width="100%">
<caption><span>Table 9: Adverse Reactions* in a Placebo-Controlled, Add-On Study in Patients 4 Years of Age and Older with PGTC <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</span></caption>
<col align="left" width="39.287%">
<col align="left" width="30.357%">
<col align="left" width="30.357%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Bold">*</span> Adverse reactions occurred in at least 5% of levetiracetam-treated patients and occurred more frequently than placebo-treated patients
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Levetiracetam</span><br><span class="Bold">(N=79)</span><br><span class="Bold">%</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">(N=84)</span><br><span class="Bold">%</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">14
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">10
</td>
<td class="Botrule Rrule" align="center" valign="top">8
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">8
</td>
<td class="Botrule Rrule" align="center" valign="top">7
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">       <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Mood swings</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
</tbody>
</table>
<p>In the placebo-controlled study, 5% of patients receiving levetiracetam and 8% receiving placebo either discontinued or had a dose reduction during the treatment period as a result of an adverse reaction.
</p>
<p>This study was too small to adequately characterize the adverse reactions that could be expected to result in discontinuation of treatment in this population. It is expected that the adverse reactions that would lead to discontinuation in this population would be similar to those resulting in discontinuation in other <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> trials (see <a href="#t4">tables 4</a> and <a href="#t8">8</a>).
</p>
<p>In addition, the following adverse reactions were seen in other controlled adult studies of levetiracetam: <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">balance disorder</span>, <span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">disturbance in attention</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s49"></a><a name="section-6.1.4"></a><p></p>
<p class="First"><span class="Underline">Comparison of Gender, Age and Race</span></p>
<p>The overall adverse reaction profile of levetiracetam was similar between females and males. There are insufficient data to support a statement regarding the distribution of adverse reactions by age and race.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s50"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience
</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of levetiracetam. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
</p>
<p>The following adverse reactions have been reported in patients receiving levetiracetam worldwide. The listing is alphabetized: abnormal liver function test, <span class="product-label-link" type="condition" conceptid="4181630" conceptname="Choreoathetosis">choreoathetosis</span>, drug reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> and systemic symptoms (DRESS), <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> (with bone marrow suppression identified in some of these cases), <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attack</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span> has been reported with levetiracetam use; recovery was observed in majority of cases where levetiracetam was discontinued. 
</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s52"></a><a name="section-7"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s53"></a><a name="section-7.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<p class="First">Levetiracetam blood levels may decrease during pregnancy <span class="Italics">[see Warnings and Precautions (<a href="#s40">5.8</a>)]</span>.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s54"></a><a name="section-7.1.1"></a><p></p>
<p class="First"><span class="Underline">Pregnancy Category C</span></p>
<p>There are no adequate and well-controlled studies in pregnant women. In animal studies, levetiracetam produced evidence of developmental toxicity, including teratogenic effects, at doses similar to or greater than human therapeutic doses. Levetiracetam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
</p>
<p>Oral administration of levetiracetam to female rats throughout pregnancy and lactation led to increased incidences of minor fetal skeletal abnormalities and retarded offspring growth pre- and/or postnatally at doses ≥350 mg/kg/day (equivalent to the maximum recommended human dose of 3,000 mg [MRHD] on a mg/m<span class="Sup">2</span> basis) and with increased pup mortality and offspring behavioral alterations at a dose of 1,800 mg/kg/day (6 times the MRHD on a mg/m<span class="Sup">2</span> basis). The developmental no effect dose was 70 mg/kg/day (0.2 times the MRHD on a mg/m<span class="Sup">2</span> basis). There was no overt maternal toxicity at the doses used in this study.
</p>
<p>Oral administration of levetiracetam to pregnant rabbits during the period of organogenesis resulted in increased embryofetal mortality and increased incidences of minor fetal skeletal abnormalities at doses ≥600 mg/kg/day (4 times MRHD on a mg/m<span class="Sup">2</span> basis) and in decreased fetal weights and increased incidences of <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> at a dose of 1,800 mg/kg/day (12 times the MRHD on a mg/m<span class="Sup">2</span> basis). The developmental no effect dose was 200 mg/kg/day (equivalent to the MRHD on a mg/m<span class="Sup">2</span> basis). Maternal toxicity was also observed at 1,800 mg/kg/day.
</p>
<p>When levetiracetam was administered orally to pregnant rats during the period of organogenesis, fetal weights were decreased and the incidence of fetal skeletal variations was increased at a dose of 3,600 mg/kg/day (12 times the MRHD). 1,200 mg/kg/day (4 times the MRHD) was a developmental no effect dose. There was no evidence of maternal toxicity in this study.
</p>
<p>Treatment of rats during the last third of gestation and throughout lactation produced no adverse developmental or maternal effects at doses of up to 1,800 mg/kg/day (6 times the MRHD on a mg/m<span class="Sup">2</span> basis).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s55"></a><a name="section-7.1.2"></a><p></p>
<p class="First"><span class="Underline">Pregnancy Registry</span></p>
<p>To provide information regarding the effects of in utero exposure to levetiracetam, physicians are advised to recommend that pregnant patients taking levetiracetam enroll in the North American Antiepileptic Drug (NAAED) pregnancy registry. This can be done by calling the toll free number 1-888-233-2334, and must be done by the patients themselves. Information on the registry can also be found at the website http://www.aedpregnancyregistry.org/.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="s56"></a><a name="section-7.2"></a><p></p>
<h2>8.2 Labor and Delivery
</h2>
<p class="First">The effect of levetiracetam on labor and delivery in humans is unknown.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s57"></a><a name="section-7.3"></a><p></p>
<h2>8.3 Nursing Mothers
</h2>
<p class="First">Levetiracetam is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from levetiracetam, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s58"></a><a name="section-7.4"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First">The safety and effectiveness of levetiracetam in the adjunctive treatment of partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in pediatric patients age 1 month to 16 years with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> have been established <span class="Italics">[see Clinical Studies (<a href="#s100">14.1</a>)]</span>. The dosing recommendation in these pediatric patients varies according to age group and is weight-based <span class="Italics">[see Dosage and Administration (<a href="#s19">2.6</a>)]</span>.
</p>
<p>The safety and effectiveness of levetiracetam as adjunctive treatment of myoclonic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in adolescents 12 years of age and older with juvenile <span class="product-label-link" type="condition" conceptid="4290772" conceptname="Myoclonic seizure">myoclonic epilepsy</span> have been established <span class="Italics">[see Clinical Studies (<a href="#s108">14.2</a>)]</span>.
</p>
<p>The safety and effectiveness of levetiracetam as adjunctive therapy in the treatment of primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span> in pediatric patients 6 years of age and older with idiopathic generalized <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> have been established <span class="Italics">[see Clinical Studies (<a href="#s109">14.3</a>)]</span>.
</p>
<p>A 3-month, randomized, double-blind, placebo-controlled study was performed to assess the neurocognitive and behavioral effects of levetiracetam as adjunctive therapy in 98 (levetiracetam N=64, placebo N=34) pediatric patients, ages 4 years to 16 years, with <span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">partial seizures</span> that were inadequately controlled. The target dose was 60 mg/kg/day. Neurocognitive effects were measured by the Leiter-R Attention and Memory (AM) Battery, which measures various aspects of a child's memory and attention.  Although no substantive differences were observed between the placebo and drug treated groups in the median change from baseline in this battery, the study was not adequate to assess formal statistical non-inferiority of the drug and placebo. The Achenbach Child Behavior Checklist (CBCL/6-18), a standardized validated tool used to assess a child's competencies and behavioral/<span class="product-label-link" type="condition" conceptid="4305081" conceptname="Emotional problems">emotional problems</span>, was also assessed in this study. An analysis of the CBCL/6-18 indicated, on average, a worsening in levetiracetam-treated patients in <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span>, one of the eight syndrome scores <span class="Italics">[see Warnings and Precautions (<a href="#s29">5.1</a>)]</span>.
</p>
<p>Studies of levetiracetam in juvenile rats (dosing from day 4 through day 52 of age) and dogs (dosing from week 3 through week 7 of age) at doses of up to 1,800 mg/kg/day (approximately 7 and 24 times, respectively, the maximum recommended pediatric dose of 60 mg/kg/day on a mg/m<span class="Sup">2</span> basis) did not indicate a potential for age-specific toxicity.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s59"></a><a name="section-7.5"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First">There were 347 subjects in clinical studies of levetiracetam that were 65 years old and over. No overall differences in safety were observed between these subjects and younger subjects. There were insufficient numbers of elderly subjects in controlled trials of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> to adequately assess the effectiveness of levetiracetam in these patients.
</p>
<p>Levetiracetam is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function <span class="Italics">[see Clinical Pharmacology (<a href="#s70">12.3</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s60"></a><a name="section-7.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">Clearance of levetiracetam is decreased in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and is correlated with creatinine clearance <span class="Italics">[see Clinical Pharmacology (<a href="#s70">12.3</a>)]</span>. Dosage adjustment is recommended for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> and supplemental doses should be given to patients after dialysis <span class="Italics">[see Dosage and Administration (<a href="#s22">2.7</a>)]</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s61"></a><a name="section-8"></a><p></p>
<h1>10 OVERDOSAGE
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s62"></a><a name="section-8.1"></a><p></p>
<h2>10.1 Signs, Symptoms and Laboratory Findings of Acute Overdosage in Humans
</h2>
<p class="First">The highest known dose of oral levetiracetam received in the clinical development program was 6,000 mg/day. Other than <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, there were no adverse reactions in the few known cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> in clinical trials. Cases of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">depressed level of consciousness</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> were observed with levetiracetam <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> in postmarketing use.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s63"></a><a name="section-8.2"></a><p></p>
<h2>10.2 Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span>
</h2>
<p class="First">There is no specific antidote for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with levetiracetam. If indicated, elimination of unabsorbed drug should be attempted by <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> or gastric lavage; usual precautions should be observed to maintain airway. General supportive care of the patient is indicated including monitoring of vital signs and observation of the patient's clinical status. A Certified Poison Control Center should be contacted for up to date information on the management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with levetiracetam.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s64"></a><a name="section-8.3"></a><p></p>
<h2>10.3 Hemodialysis
</h2>
<p class="First">Standard hemodialysis procedures result in significant clearance of levetiracetam (approximately 50% in 4 hours) and should be considered in cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Although hemodialysis has not been performed in the few known cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, it may be indicated by the patient's clinical state or in patients with significant <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s65"></a><a name="section-9"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First">Levetiracetam Injection is an antiepileptic drug available as a clear, colorless, sterile solution (100 mg/mL) for intravenous administration.
</p>
<p>The chemical name of levetiracetam, a single enantiomer, is (-)-(S)-α-ethyl-2-oxo-1-pyrrolidine acetamide, its molecular formula is C<span class="Sub">8</span>H<span class="Sub">14</span>N<span class="Sub">2</span>O<span class="Sub">2</span> and its molecular weight is 170.21. Levetiracetam is chemically unrelated to existing antiepileptic drugs (AEDs). It has the following structural formula:
</p>
<p><a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f00d8f59-c333-48ad-aca3-98a49bcd228e&amp;name=lev00-0008-01.jpg"></p>
<p>Levetiracetam is a white to off-white crystalline powder with a <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> odor and a bitter taste. It is very soluble in water (104.0 g/100 mL). It is freely soluble in chloroform (65.3 g/100 mL) and in methanol (53.6 g/100 mL), soluble in ethanol (16.5 g/100 mL), sparingly soluble in acetonitrile (5.7 g/100 mL) and practically insoluble in n-hexane. (Solubility limits are expressed as g/100 mL solvent.)
</p>
<p>Levetiracetam Injection contains 100 mg of levetiracetam per mL. It is supplied in single-dose 5 mL vials containing 500 mg levetiracetam, water for injection, 45 mg sodium chloride, and buffered at approximately pH 5.5 with glacial acetic acid and 8.2 mg sodium acetate trihydrate. Levetiracetam Injection must be diluted prior to intravenous infusion <span class="Italics">[see Dosage and Administration (<a href="#s19">2.6</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s66"></a><a name="section-10"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s67"></a><a name="section-10.1"></a><p></p>
<h2>12.1 Mechanism of Action
</h2>
<p class="First">The precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. The antiepileptic activity of levetiracetam was assessed in a number of animal models of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epileptic seizures</span>. Levetiracetam did not inhibit single <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> induced by maximal stimulation with electrical current or different chemoconvulsants and showed only minimal activity in submaximal stimulation and in threshold tests. Protection was observed, however, against secondarily generalized activity from <span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">focal seizures</span> induced by pilocarpine and kainic acid, two chemoconvulsants that induce <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> that mimic some features of human <span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">complex partial seizures</span> with secondary generalization. Levetiracetam also displayed inhibitory properties in the kindling model in rats, another model of human <span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">complex partial seizures</span>, both during kindling development and in the fully kindled state. The predictive value of these animal models for specific types of human <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> is uncertain.
</p>
<p><span class="Italics">In vitro</span> and <span class="Italics">in vivo</span> recordings of epileptiform activity from the hippocampus have shown that levetiracetam inhibits burst firing without affecting normal neuronal <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span>, suggesting that levetiracetam may selectively prevent hypersynchronization of epileptiform burst firing and propagation of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> activity.
</p>
<p>Levetiracetam at concentrations of up to 10 μM did not demonstrate binding affinity for a variety of known receptors, such as those associated with benzodiazepines, GABA (gamma-aminobutyric acid), glycine, NMDA (N-methyl-D-aspartate), re-uptake sites, and second messenger systems. Furthermore, <span class="Italics">in vitro</span> studies have failed to find an effect of levetiracetam on neuronal voltage-gated sodium or T-type calcium currents and levetiracetam does not appear to directly facilitate GABAergic neurotransmission. However, <span class="Italics">in vitro</span> studies have demonstrated that levetiracetam opposes the activity of negative modulators of GABA- and glycine-gated currents and partially inhibits N-type calcium currents in neuronal cells.
</p>
<p>A saturable and stereoselective neuronal binding site in rat brain tissue has been described for levetiracetam. Experimental data indicate that this binding site is the synaptic <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicle</span> protein SV2A, thought to be involved in the regulation of <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicle</span> exocytosis. Although the molecular significance of levetiracetam binding to synaptic <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicle</span> protein SV2A is not understood, levetiracetam and related analogs showed a rank order of affinity for SV2A which correlated with the potency of their antiseizure activity in audiogenic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>-prone mice. These findings suggest that the interaction of levetiracetam with the SV2A protein may contribute to the antiepileptic mechanism of action of the drug.
</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s68"></a><a name="section-10.2"></a><p></p>
<h2>12.2 Pharmacodynamics
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s69"></a><a name="section-10.2.1"></a><p></p>
<p class="First"><span class="Italics Underline">Effects on QTc Interval</span></p>
<p>The effect of levetiracetam on QTc prolongation was evaluated in a randomized, double-blind, positive-controlled (moxifloxacin 400 mg) and placebo-controlled crossover study of levetiracetam (1,000 mg or 5,000 mg) in 52 healthy subjects. The upper bound of the 90% confidence interval for the largest placebo-adjusted, baseline-corrected QTc was below 10 milliseconds. Therefore, there was no evidence of significant QTc prolongation in this study.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s70"></a><a name="section-10.3"></a><p></p>
<h2>12.3  Pharmacokinetics
</h2>
<p class="First">Equivalent doses of intravenous (IV) levetiracetam and oral levetiracetam result in equivalent C<span class="Sub">max</span>, C<span class="Sub">min</span>, and total systemic exposure to levetiracetam when the IV levetiracetam is administered as a 15-minute infusion.
</p>
<p>The pharmacokinetics of levetiracetam have been studied in healthy adult subjects, adults and pediatric patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, elderly subjects, and subjects with renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s71"></a><a name="section-10.3.1"></a><p></p>
<p class="First"><span class="Underline">Overview</span></p>
<p>Levetiracetam is rapidly and almost completely absorbed after oral administration. Levetiracetam injection and tablets are bioequivalent. The pharmacokinetics of levetiracetam are linear and time-invariant, with low intra- and inter-subject variability. Levetiracetam is not significantly protein-bound (&lt;10% bound) and its volume of distribution is close to the volume of intracellular and extracellular water. Sixty-six percent (66%) of the dose is renally excreted unchanged. The major metabolic pathway of levetiracetam (24% of dose) is an enzymatic hydrolysis of the acetamide group. It is not liver cytochrome P450 dependent. The metabolites have no known pharmacological activity and are renally excreted. Plasma half-life of levetiracetam across studies is approximately 6 to 8 hours. It is increased in the elderly (primarily due to impaired renal clearance) and in subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s72"></a><a name="section-10.3.2"></a><p></p>
<p class="First"><span class="Underline">Distribution</span></p>
<p>The equivalence of levetiracetam injection and the oral formulation was demonstrated in a bioavailability study of 17 healthy volunteers. In this study, levetiracetam 1,500 mg was diluted in 100 mL 0.9% sterile saline solution and was infused over 15 minutes. The selected infusion rate provided plasma concentrations of levetiracetam at the end of the infusion period similar to those achieved at T<span class="Sub">max</span> after an equivalent oral dose. It is demonstrated that levetiracetam 1,500 mg intravenous infusion is equivalent to levetiracetam 3 x 500 mg oral tablets. The time independent pharmacokinetic profile of levetiracetam was demonstrated following 1,500 mg intravenous infusion for 4 days with BID dosing. The AUC<span class="Sub">(0-12)</span> at steady-state was equivalent to AUC<span class="Sub">inf</span> following an equivalent single dose.
</p>
<p>Levetiracetam and its major metabolite are less than 10% bound to plasma proteins; clinically significant interactions with other drugs through competition for protein binding sites are therefore unlikely.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s73"></a><a name="section-10.3.3"></a><p></p>
<p class="First"><span class="Underline">Metabolism</span></p>
<p>Levetiracetam is not extensively metabolized in humans. The major metabolic pathway is the enzymatic hydrolysis of the acetamide group, which produces the carboxylic acid metabolite, ucb L057 (24% of dose) and is not dependent on any liver cytochrome P450 isoenzymes. The major metabolite is inactive in animal <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> models. Two minor metabolites were identified as the product of hydroxylation of the 2-oxo-pyrrolidine ring (2% of dose) and opening of the 2-oxo-pyrrolidine ring in position 5 (1% of dose). There is no enantiomeric interconversion of levetiracetam or its major metabolite.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s74"></a><a name="section-10.3.4"></a><p></p>
<p class="First"><span class="Underline">Elimination</span></p>
<p>Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose, route of administration or repeated administration. Levetiracetam is eliminated from the systemic circulation by renal excretion as unchanged drug which represents 66% of administered dose. The total body clearance is 0.96 mL/min/kg and the renal clearance is 0.6 mL/min/kg. The mechanism of excretion is glomerular filtration with subsequent partial tubular reabsorption. The metabolite ucb L057 is excreted by glomerular filtration and active tubular secretion with a renal clearance of 4 mL/min/kg. Levetiracetam elimination is correlated to creatinine clearance. Levetiracetam clearance is reduced in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see Dosage and Administration (<a href="#s19">2.6</a>) and Use in Specific Populations (<a href="#s60">8.6</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s75"></a><a name="section-10.3.5"></a><p></p>
<p class="First"><span class="Underline">Specific Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s76"></a><a name="section-10.3.5.1"></a><p></p>
<p class="First"><span class="Italics">Elderly</span></p>
<p>Pharmacokinetics of levetiracetam were evaluated in 16 elderly subjects (age 61 to 88 years) with creatinine clearance ranging from 30 to 74 mL/min. Following oral administration of twice-daily dosing for 10 days, total body clearance decreased by 38% and the half-life was 2.5 hours longer in the elderly compared to healthy adults. This is most likely due to the decrease in renal function in these subjects.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s77"></a><a name="section-10.3.5.2"></a><p></p>
<p class="First"><span class="Italics">Pediatric Patients</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s78"></a><a name="section-10.3.5.2.1"></a><p></p>
<ul class="Disc"><li>
<p class="First">Intravenous Formulation
</p>
<p>A population pharmacokinetic analysis for the intravenous formulation was conducted in 49 pediatric patients (1 month to &lt; 16 years of age) weighing 3 to 79 kg. Patients received levetiracetam as a 15-minute IV infusion at doses between 14 mg/kg/day and 60 mg/kg/day twice daily. Plasma concentrations and model derived steady-state exposure AUC<span class="Sub">(0-12)</span> were within the range of the exposure observed in pediatric patients receiving equivalent doses of the oral solution.
</p>
</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s79"></a><a name="section-10.3.5.2.2"></a><p></p>
<ul class="Disc"><li>
<p class="First">Oral Formulations
</p>
<p>Pharmacokinetics of levetiracetam were evaluated in 24 pediatric patients (age 6 to 12 years) after single oral dose (20 mg/kg) of the immediate release formulation of levetiracetam. The body weight adjusted apparent clearance of levetiracetam was approximately 40% higher than in adults.
</p>
<p><br>A repeat dose pharmacokinetic study was conducted in pediatric patients (age 4 to 12 years) at doses of 20 mg/kg/day, 40 mg/kg/day, and 60 mg/kg/day of the immediate release formulation of levetiracetam. The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses, with a T<span class="Sub">max</span> of about 1 hour and a t<span class="Sub">1/2</span> of 5 hours across all dosing levels. The pharmacokinetics of levetiracetam in pediatric patients was linear between 20 to 60 mg/kg/day. The potential interaction of levetiracetam with other AEDs was also evaluated in these patients. Levetiracetam had no significant effect on the plasma concentrations of carbamazepine, valproic acid, topiramate or lamotrigine. However, there was about a 22% increase of apparent clearance of levetiracetam when it was co-administered with an enzyme-inducing AED (e.g., carbamazepine).
</p>
<p><br>Following single dose administration (20 mg/kg) of a 10% oral solution to pediatric patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (1 month to &lt; 4 years), levetiracetam was rapidly absorbed and peak plasma concentrations were observed approximately 1 hour after dosing. Levetiracetam half-life in pediatric patients 1 month to &lt; 4 years with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> was shorter (5.3 h) than in adults (7.2 h), and apparent clearance (1.5 mL/min/kg) was faster than in adults (0.96 mL/min/kg).
</p>
<p><br>Population pharmacokinetic analysis showed that body weight was significantly correlated to the clearance of levetiracetam in pediatric patients; clearance increased with an increase in body weight.
</p>
</li></ul>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s80"></a><a name="section-10.3.5.3"></a><p></p>
<p class="First"><span class="Italics">Pregnancy</span></p>
<p>Levetiracetam levels may decrease during pregnancy.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s81"></a><a name="section-10.3.5.4"></a><p></p>
<p class="First"><span class="Italics">Gender</span></p>
<p>Levetiracetam C<span class="Sub">max</span> and AUC were 20% higher in women (N=11) compared to men (N=12). However, clearances adjusted for body weight were comparable.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s82"></a><a name="section-10.3.5.5"></a><p></p>
<p class="First"><span class="Italics">Race</span></p>
<p>Formal pharmacokinetic studies of the effects of race have not been conducted. Cross-study comparisons involving Caucasians (N=12) and Asians (N=12), however, show that pharmacokinetics of levetiracetam were comparable between the two races. Because levetiracetam is primarily renally excreted and there are no important racial differences in creatinine clearance, pharmacokinetic differences due to race are not expected.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s83"></a><a name="section-10.3.5.6"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>The disposition of levetiracetam was studied in adult subjects with varying degrees of renal function. Total body clearance of levetiracetam is reduced in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> by 40% in the mild group (CLcr = 50 to 80 mL/min), 50% in the moderate group (CLcr = 30 to 50 mL/min) and 60% in the severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> group (CLcr &lt;30 mL/min). Clearance of levetiracetam is correlated with creatinine clearance.
</p>
<p>In anuric (end stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>) patients, the total body clearance decreased 70% compared to normal subjects (CLcr &gt;80 mL/min). Approximately 50% of the pool of levetiracetam in the body is removed during a standard 4 hour hemodialysis procedure [<span class="Italics">see Dosage and Administration (<a href="#s22">2.7</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s84"></a><a name="section-10.3.5.7"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>In subjects with mild (Child-Pugh A) to moderate (Child-Pugh B) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, the pharmacokinetics of levetiracetam were unchanged. In patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh C), total body clearance was 50% that of normal subjects, but decreased renal clearance accounted for most of the decrease. No dose adjustment is needed for patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s85"></a><a name="section-10.3.6"></a><p></p>
<p class="First"><span class="Underline">Drug Interactions</span></p>
<p><span class="Italics">In vitro</span> data on metabolic interactions indicate that levetiracetam is unlikely to produce, or be subject to, <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span>. Levetiracetam and its major metabolite, at concentrations well above C<span class="Sub">max</span> levels achieved within the therapeutic dose range, are neither inhibitors of, nor high affinity substrates for, human liver cytochrome P450 isoforms, epoxide hydrolase or UDP-glucuronidation enzymes. In addition, levetiracetam does not affect the <span class="Italics">in vitro</span> glucuronidation of valproic acid.
</p>
<p>Potential <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> of or with levetiracetam were assessed in clinical pharmacokinetic studies (phenytoin, valproate, warfarin, digoxin, oral contraceptive, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> patients.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s86"></a><a name="section-10.3.6.1"></a><p></p>
<p class="First"><span class="Italics">Phenytoin</span></p>
<p>Levetiracetam (3,000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>. Pharmacokinetics of levetiracetam were also not affected by phenytoin.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s87"></a><a name="section-10.3.6.2"></a><p></p>
<p class="First"><span class="Italics">Valproate</span></p>
<p>Levetiracetam (1,500 mg twice daily) did not alter the pharmacokinetics of valproate in healthy volunteers. Valproate 500 mg twice daily did not modify the rate or extent of levetiracetam absorption or its plasma clearance or urinary excretion. There also was no effect on exposure to and the excretion of the primary metabolite, ucb L057.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s88"></a><a name="section-10.3.6.3"></a><p></p>
<p class="First"><span class="Italics">Other Antiepileptic Drugs</span></p>
<p>Potential drug interactions between levetiracetam and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies. These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of levetiracetam.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s89"></a><a name="section-10.3.6.4"></a><p></p>
<p class="First"><span class="Italics">Effect of AEDs in Pediatric Patients</span></p>
<p>There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing AEDs. Dose adjustment is not recommended. Levetiracetam had no effect on plasma concentrations of carbamazepine, valproate, topiramate, or lamotrigine.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s90"></a><a name="section-10.3.6.5"></a><p></p>
<p class="First"><span class="Italics">Oral Contraceptives</span></p>
<p>Levetiracetam (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely. Coadministration of this oral contraceptive did not influence the pharmacokinetics of levetiracetam.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s91"></a><a name="section-10.3.6.6"></a><p></p>
<p class="First"><span class="Italics">Digoxin</span></p>
<p>Levetiracetam (1,000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of digoxin given as a 0.25 mg dose every day. Coadministration of digoxin did not influence the pharmacokinetics of levetiracetam.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s92"></a><a name="section-10.3.6.7"></a><p></p>
<p class="First"><span class="Italics">Warfarin</span></p>
<p>Levetiracetam (1,000 mg twice daily) did not influence the pharmacokinetics of R and S warfarin. <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time was not affected by levetiracetam. Coadministration of warfarin did not affect the pharmacokinetics of levetiracetam.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s93"></a><a name="section-10.3.6.8"></a><p></p>
<p class="First"><span class="Italics">Probenecid</span></p>
<p>Probenecid, a renal tubular secretion blocking agent, administered at a dose of 500 mg four times a day, did not change the pharmacokinetics of levetiracetam 1,000 mg twice daily. C<span class="Sup">ss</span><span class="Sub">max</span> of the metabolite, ucb L057, was approximately doubled in the presence of probenecid while the fraction of drug excreted unchanged in the urine remained the same. Renal clearance of ucb L057 in the presence of probenecid decreased 60%, probably related to competitive inhibition of tubular secretion of ucb L057. The effect of levetiracetam on probenecid was not studied.
</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s94"></a><a name="section-11"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s95"></a><a name="section-11.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s96"></a><a name="section-11.1.1"></a><p></p>
<p class="First"><span class="Underline">Carcinogenesis</span></p>
<p>Rats were dosed with levetiracetam in the diet for 104 weeks at doses of 50, 300 and 1,800 mg/kg/day. The highest dose is 6 times the maximum recommended daily human dose (MRHD) of 3,000 mg on a mg/m<span class="Sup">2</span> basis and it also provided systemic exposure (AUC) approximately 6 times that achieved in humans receiving the MRHD. There was no evidence of carcinogenicity. In mice, oral administration of levetiracetam for 80 weeks (doses up to 960 mg/kg/day) or 2 years (doses up to 4,000 mg/kg/day, lowered to 3,000 mg/kg/day after 45 weeks due to intolerability) was not associated with an increase in tumors. The highest dose tested in mice for 2 years (3,000 mg/kg/day) is approximately 5 times the MRHD on a mg/m<span class="Sup">2</span> basis.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s97"></a><a name="section-11.1.2"></a><p></p>
<p class="First"><span class="Underline">Mutagenesis</span></p>
<p>Levetiracetam was not mutagenic in the Ames test or in mammalian cells <span class="Italics">in vitro</span> in the Chinese hamster ovary/HGPRT locus assay. It was not clastogenic in an <span class="Italics">in vitro</span> analysis of metaphase chromosomes obtained from Chinese hamster ovary cells or in an <span class="Italics">in vivo</span> mouse micronucleus assay. The hydrolysis product and major human metabolite of levetiracetam (ucb L057) was not mutagenic in the Ames test or the <span class="Italics">in vitro</span> mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s98"></a><a name="section-11.1.3"></a><p></p>
<p class="First"><span class="Underline">Impairment of Fertility</span></p>
<p>No adverse effects on male or female fertility or reproductive performance were observed in rats at oral doses up to 1,800 mg/kg/day (6 times the maximum recommended human dose on a mg/m<span class="Sup">2</span> or systemic exposure [AUC] basis).
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s99"></a><a name="section-12"></a><p></p>
<h1>14 CLINICAL STUDIES
</h1>
<p class="First">All clinical studies supporting the efficacy of levetiracetam utilized oral formulations. The finding of efficacy of levetiracetam injection is based on the results of studies using an oral formulation of levetiracetam, and on the demonstration of comparable bioavailability of the oral and parenteral formulations <span class="Italics">[see Pharmacokinetics (<a href="#s70">12.3</a>)]</span>.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s100"></a><a name="section-12.1"></a><p></p>
<h2>14.1 Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s101"></a><a name="section-12.1.1"></a><p></p>
<p class="First"><span class="Underline">Effectiveness in Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> in Adults with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></span></p>
<p>The effectiveness of levetiracetam as adjunctive therapy (added to other antiepileptic drugs) in adults was established in three multicenter, randomized, double-blind, placebo-controlled clinical studies in patients who had refractory partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> with or without secondary generalization. The tablet formulation was used in all these studies. In these studies, 904 patients were randomized to placebo, 1,000 mg, 2,000 mg, or 3,000 mg/day. Patients enrolled in Study 1 or Study 2 had refractory partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> for at least two years and had taken two or more classical AEDs. Patients enrolled in Study 3 had refractory partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> for at least 1 year and had taken one classical AED. At the time of the study, patients were taking a stable dose regimen of at least one and could take a maximum of two AEDs. During the baseline period, patients had to have experienced at least two partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> during each 4-week period.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s102"></a><a name="section-12.1.2"></a><p></p>
<p class="First"><span class="Italics">Study 1</span></p>
<p>Study 1 was a double-blind, placebo-controlled, parallel-group study conducted at 41 sites in the United States comparing levetiracetam 1,000 mg/day (N=97), levetiracetam 3,000 mg/day (N=101), and placebo (N=95) given in equally divided doses twice daily. After a prospective baseline period of 12 weeks, patients were randomized to one of the three treatment groups described above. The 18-week treatment period consisted of a 6-week titration period, followed by a 12-week fixed dose evaluation period, during which concomitant AED regimens were held constant. The primary measure of effectiveness was a between group comparison of the percent reduction in weekly partial <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency relative to placebo over the entire randomized treatment period (titration + evaluation period). Secondary outcome variables included the responder rate (incidence of patients with ≥50% reduction from baseline in partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency). The results of the analysis of Study 1 are displayed in <a href="#t10">Table 10</a>.
</p>
<a name="t10"></a><table width="100%">
<caption><span>Table 10: Reduction in Mean Over Placebo in Weekly Frequency of Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> in Study 1
</span></caption>
<col align="left" width="33.925%">
<col align="left" width="19.650%">
<col align="left" width="25.000%">
<col align="left" width="21.425%">
<tfoot><tr class="First Last"><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Sup">*</span>statistically significant versus placebo
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="3" valign="top"></td>
<td class="Rrule Toprule" align="center" valign="middle">Placebo
</td>
<td class="Rrule Toprule" align="center" valign="middle">Levetiracetam
</td>
<td class="Rrule Toprule" align="center" valign="middle">Levetiracetam
</td>
</tr>
<tr>
<td class="Rrule" align="center" valign="middle">(N=95)
</td>
<td class="Rrule" align="center" valign="middle">1,000 mg/day
</td>
<td class="Rrule" align="center" valign="middle">3,000 mg/day
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">(N=97)
</td>
<td class="Botrule Rrule" align="center" valign="top">(N=101)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="bottom">Percent reduction in partial <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency over placebo
</td>
<td class="Botrule Rrule" align="center" valign="middle">–
</td>
<td class="Botrule Rrule" align="center" valign="middle">26.1%<span class="Sup">*</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">30.1%<span class="Sup">*</span>
</td>
</tr>
</tbody>
</table>
<p>The percentage of patients (y-axis) who achieved ≥50% reduction in weekly <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> rates from baseline in partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency over the entire randomized treatment period (titration + evaluation period) within the three treatment groups (x-axis) is presented in <a href="#fig1">Figure 1</a>.
</p>
<p><a name="fig1"></a><span class="Bold">Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1</span></p>
<p><a name="f02"></a><img alt="Figure 1
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f00d8f59-c333-48ad-aca3-98a49bcd228e&amp;name=lev00-0008-02.jpg"></p>
<p><span class="Bold">*</span>statistically significant versus placebo
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s103"></a><a name="section-12.1.3"></a><p></p>
<p class="First"><span class="Italics">Study 2</span></p>
<p>Study 2 was a double-blind, placebo-controlled, crossover study conducted at 62 centers in Europe comparing levetiracetam 1,000 mg/day (N=106), levetiracetam 2,000 mg/day (N=105), and placebo (N=111) given in equally divided doses twice daily.
</p>
<p>The first period of the study (Period A) was designed to be analyzed as a parallel-group study. After a prospective baseline period of up to 12 weeks, patients were randomized to one of the three treatment groups described above. The 16-week treatment period consisted of the 4-week titration period followed by a 12-week fixed dose evaluation period, during which concomitant AED regimens were held constant. The primary measure of effectiveness was a between group comparison of the percent reduction in weekly partial <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency relative to placebo over the entire randomized treatment period (titration + evaluation period). Secondary outcome variables included the responder rate (incidence of patients with ≥50% reduction from baseline in partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency). The results of the analysis of Period A are displayed in <a href="#t11">Table 11</a>.
</p>
<a name="t11"></a><table width="100%">
<caption><span>Table 11:  Reduction in Mean Over Placebo in Weekly Frequency of Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> in Study 2: Period A
</span></caption>
<col align="left" width="33.925%">
<col align="left" width="17.850%">
<col align="left" width="25.000%">
<col align="left" width="23.225%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="3" valign="top"></td>
<td class="Rrule Toprule" align="center" valign="middle">Placebo
</td>
<td class="Rrule Toprule" align="center" valign="middle">Levetiracetam
</td>
<td class="Rrule Toprule" align="center" valign="middle">Levetiracetam
</td>
</tr>
<tr>
<td class="Rrule" align="center" valign="middle">(N=111)
</td>
<td class="Rrule" align="center" valign="middle">1,000 mg/day
</td>
<td class="Rrule" align="center" valign="middle">2,000 mg/day
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">(N=106)
</td>
<td class="Botrule Rrule" align="center" valign="top">(N=105)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="bottom">Percent reduction in partial <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency over placebo
</td>
<td class="Botrule Rrule" align="center" valign="middle">–
</td>
<td class="Botrule Rrule" align="center" valign="middle">17.1%<span class="Sup">*</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">21.4%<span class="Sup">*</span>
</td>
</tr>
</tbody>
</table>
<p><span class="Sup">*</span>statistically significant versus placebo
</p>
<p>The percentage of patients (y-axis) who achieved ≥50% reduction in weekly <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> rates from baseline in partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency over the entire randomized treatment period (titration + evaluation period) within the three treatment groups (x-axis) is presented in <a href="#fig2">Figure 2</a>.
</p>
<p><a name="fig2"></a><span class="Bold">Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A</span></p>
<p><a name="f03"></a><img alt="Figure 2
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f00d8f59-c333-48ad-aca3-98a49bcd228e&amp;name=lev00-0008-03.jpg"></p>
<p><span class="Bold">*</span>statistically significant versus placebo
</p>
<p>The comparison of levetiracetam 2,000 mg/day to levetiracetam 1,000 mg/day for responder rate was statistically significant (<span class="Italics">P</span>=0.02). Analysis of the trial as a cross-over yielded similar results.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s104"></a><a name="section-12.1.4"></a><p></p>
<p class="First"><span class="Italics">Study 3</span></p>
<p>Study 3 was a double-blind, placebo-controlled, parallel-group study conducted at 47 centers in Europe comparing levetiracetam 3,000 mg/day (N=180) and placebo (N=104) in patients with refractory partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, with or without secondary generalization, receiving only one concomitant AED. Study drug was given in two divided doses. After a prospective baseline period of 12 weeks, patients were randomized to one of two treatment groups described above. The 16-week treatment period consisted of a 4-week titration period, followed by a 12-week fixed dose evaluation period, during which concomitant AED doses were held constant. The primary measure of effectiveness was a between group comparison of the percent reduction in weekly <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency relative to placebo over the entire randomized treatment period (titration + evaluation period). Secondary outcome variables included the responder rate (incidence of patients with ≥50% reduction from baseline in partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency). <a href="#t12">Table 12</a> displays the results of the analysis of Study 3.
</p>
<a name="t12"></a><table width="100%">
<caption><span>Table 12: Reduction in Mean Over Placebo in Weekly Frequency of Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> in Study 3
</span></caption>
<col align="left" width="33.467%">
<col align="left" width="27.233%">
<col align="left" width="39.300%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">*</span>statistically significant versus placebo
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="3" valign="top"></td>
<td class="Rrule Toprule" align="center" valign="middle">Placebo
</td>
<td class="Rrule Toprule" align="center" valign="middle">Levetiracetam
</td>
</tr>
<tr>
<td class="Rrule" align="center" valign="middle">(N=104)
</td>
<td class="Rrule" align="center" valign="middle">3,000 mg/day
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">(N=180)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">Percent reduction in partial <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency over placebo
</td>
<td class="Botrule Rrule" align="center" valign="middle">–
</td>
<td class="Botrule Rrule" align="center" valign="middle">23.0%<span class="Sup">*</span>
</td>
</tr>
</tbody>
</table>
<p>The percentage of patients (y-axis) who achieved ≥50% reduction in weekly <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> rates from baseline in partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency over the entire randomized treatment period (titration + evaluation period) within the two treatment groups (x-axis) is presented in <a href="#fig3">Figure 3</a>.
</p>
<p><a name="fig3"></a><span class="Bold">Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3</span></p>
<p><a name="f04"></a><img alt="Figure 3
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f00d8f59-c333-48ad-aca3-98a49bcd228e&amp;name=lev00-0008-04.jpg"></p>
<p><span class="Bold">*</span>statistically significant versus placebo
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s105"></a><a name="section-12.1.5"></a><p></p>
<p class="First"><span class="Underline">Effectiveness in Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> in Pediatric Patients 4 Years to 16 Years with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></span></p>
<p>Study 4 was a multicenter, randomized double-blind, placebo-controlled study, in pediatric patients 4 to 16 years of age with <span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">partial seizures</span> uncontrolled by standard antiepileptic drugs (AEDs). Study 4 was conducted at 60 sites in North America. The study consisted of an 8-week baseline period and 4-week titration period followed by a 10-week evaluation period. Eligible patients who still experienced, on a stable dose of 1-2 AEDs, at least 4 partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> during the 4 weeks prior to screening, as well as at least 4 partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in each of the two 4-week baseline periods, were randomized to receive either levetiracetam or placebo. Dosing was initiated at a dose of 20 mg/kg/day in two divided doses. During the treatment period, levetiracetam doses were adjusted in 20 mg/kg/day increments, at 2-week intervals to the target dose of 60 mg/kg/day. The primary measure of efficacy was a between group comparison of the percent reduction in weekly partial <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency relative to placebo over the entire 14-week randomized treatment period (titration + evaluation period). Secondary outcome variables included the responder rate (incidence of patients with ≥ 50% reduction from baseline in partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency per week). The enrolled population included 198 patients (levetiracetam N=101, placebo N=97) with refractory partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, whether or not secondarily generalized. <a href="#t13">Table 13</a> displays the results of Study 4.
</p>
<a name="t13"></a><table width="100%">
<caption><span>Table 13: Reduction in Mean Over Placebo in Weekly Frequency of Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> in Study 4
</span></caption>
<col align="left" width="33.333%">
<col align="left" width="33.333%">
<col align="left" width="33.333%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Bold"><span class="Sup">*</span></span>statistically significant versus placebo
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">Placebo<br>(N=97)
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">Levetiracetam<br>(N=101)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Percent reduction in partial <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency over placebo
</td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">-</span></td>
<td class="Botrule Rrule" align="center" valign="middle">26.8%<span class="Bold"><span class="Sup">*</span></span>
</td>
</tr>
</tbody>
</table>
<p>The percentage of patients (y-axis) who achieved ≥50% reduction in weekly <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> rates from baseline in partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency over the entire randomized treatment period (titration + evaluation period) within the two treatment groups (x-axis) is presented in <a href="#fig4">Figure 4</a>.
</p>
<p><a name="fig4"></a><span class="Bold">Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4</span></p>
<p><a name="f05"></a><img alt="Figure 4
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f00d8f59-c333-48ad-aca3-98a49bcd228e&amp;name=lev00-0008-05.jpg"></p>
<p><span class="Bold">*</span>statistically significant versus placebo
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s107"></a><a name="section-12.1.6"></a><p></p>
<p class="First"><span class="Underline">Effectiveness in Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> in Pediatric Patients 1 Month to &lt;4 Years with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></span></p>
<p>Study 5 was a multicenter, randomized double-blind, placebo-controlled study, in pediatric patients 1 month to less than 4 years of age with <span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">partial seizures</span>, uncontrolled by standard epileptic drugs (AEDs). Study 5 was conducted at 62 sites in North America, South America, and Europe. Study 5 consisted of a 5-day evaluation period, which included a 1-day titration period followed by a 4-day maintenance period. Eligible patients who experienced, on a stable dose of 1-2 AEDs, at least 2 partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> during the 48-hour baseline video EEG were randomized to receive either levetiracetam or placebo. Randomization was stratified by age range as follows: 1 month to less than 6 months of age (N=4 treated with levetiracetam), 6 months to less than 1 year of age (N=8 treated with levetiracetam), 1 year to less than 2 years of age (N=20 treated with levetiracetam), and 2 years to less than 4 years of age (N=28 treated with levetiracetam). Levetiracetam dosing was determined by age and weight as follows: children 1 month to less than 6 months old were randomized to a target dose of 40 mg/kg/day, and children 6 months to less than 4 years old were randomized to a target dose of 50 mg/kg/day. The primary measure of efficacy was the responder rate (percent of patients with ≥ 50% reduction from baseline in average daily partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency) assessed by a blinded central reader using a 48-hour video EEG performed during the last two days of the 4-day maintenance period. The enrolled population included 116 patients (levetiracetam N=60, placebo N=56) with refractory partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, whether or not secondarily generalized. A total of 109 patients were included in the efficacy analysis. A statistically significant difference between levetiracetam and placebo was observed in Study 5 (see <a href="#fig5">Figure 5</a>). The treatment effect associated with levetiracetam was consistent across age groups.
</p>
<p><a name="fig5"></a><span class="Bold">Figure 5: Responder Rate for All Patients Ages 1 Month to &lt; 4 Years (≥ 50% Reduction from Baseline) in Study 5</span></p>
<p><a name="f06"></a><img alt="Figure 5
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f00d8f59-c333-48ad-aca3-98a49bcd228e&amp;name=lev00-0008-06.jpg"></p>
<p><span class="Bold">*</span>statistically significant versus placebo
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s108"></a><a name="section-12.2"></a><p></p>
<h2>14.2 Myoclonic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> in Patients with Juvenile <span class="product-label-link" type="condition" conceptid="4290772" conceptname="Myoclonic seizure">Myoclonic Epilepsy</span>
</h2>
<p class="First">Study 6 was a multicenter, randomized, double-blind, placebo-controlled study in patients 12 years of age and older with juvenile <span class="product-label-link" type="condition" conceptid="4290772" conceptname="Myoclonic seizure">myoclonic epilepsy</span> (JME) experiencing myoclonic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. Study 6 was conducted at 37 sites in 14 countries. Eligible patients on a stable dose of 1 antiepileptic drug (AED) experiencing one or more myoclonic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> per day for at least 8 days during the prospective 8-week baseline period were randomized to either levetiracetam or placebo (levetiracetam N=60, placebo N=60). Patients were titrated over 4 weeks to a target dose of 3,000 mg/day and treated at a stable dose of 3,000 mg/day over 12 weeks (evaluation period). Study drug was given in 2 divided doses. The primary measure of efficacy was the proportion of patients with at least 50% reduction in the number of days per week with one or more myoclonic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> during the treatment period (titration + evaluation periods) as compared to baseline. <a href="#t14">Table 14</a> displays the results for the 113 patients with JME in this study. Of 120 patients enrolled, 113 had a diagnosis of confirmed or suspected JME. The results of Study 6 are displayed in <a href="#t14">Table 14</a>.
</p>
<a name="t14"></a><table width="100%">
<caption><span>Table 14: Responder Rate (≥50% Reduction from Baseline) in Myoclonic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Days per Week in Study 6
</span></caption>
<col align="left" width="37.500%">
<col align="left" width="32.133%">
<col align="left" width="30.367%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">*</span>statistically significant versus placebo
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">Placebo<br>(N=59)
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">Levetiracetam<br>(N=54)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">Percentage of responders
</td>
<td class="Botrule Rrule" align="center" valign="middle">23.7%
</td>
<td class="Botrule Rrule" align="center" valign="middle">60.4%<span class="Sup">*</span>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s109"></a><a name="section-12.3"></a><p></p>
<h2>14.3 Primary Generalized Tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">Clonic Seizures</span>
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s110"></a><a name="section-12.3.1"></a><p></p>
<p class="First"><span class="Underline">Effectiveness in Primary Generalized Tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">Clonic Seizures</span> in Patients ≥6 years of age</span></p>
<p>Study 7 was a multicenter, randomized, double-blind, placebo-controlled study in patients 6 years of age and older with idiopathic generalized <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> experiencing primary generalized tonic-clonic (PGTC) <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. Study 7 was conducted at 50 sites in 8 countries. Eligible patients on a stable dose of 1 or 2 antiepileptic drugs (AEDs) experiencing at least 3 PGTC <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> during the 8-week combined baseline period (at least one PGTC <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> during the 4 weeks prior to the prospective baseline period and at least one PGTC <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> during the 4-week prospective baseline period) were randomized to either levetiracetam or placebo. The 8-week combined baseline period is referred to as “baseline? in the remainder of this section. Patients were titrated over 4 weeks to a target dose of 3,000 mg/day for adults or a pediatric target dose of 60 mg/kg/day and treated at a stable dose of 3,000 mg/day (or 60 mg/kg/day for children) over 20 weeks (evaluation period). Study drug was given in 2 equally divided doses per day. The primary measure of efficacy was the percent reduction from baseline in weekly PGTC <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency for levetiracetam and placebo treatment groups over the treatment period (titration + evaluation periods). The population included 164 patients (levetiracetam N=80, placebo N=84) with idiopathic generalized <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (predominately juvenile <span class="product-label-link" type="condition" conceptid="4290772" conceptname="Myoclonic seizure">myoclonic epilepsy</span>, juvenile absence <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, childhood absence <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, or <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> with <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">Grand Mal seizures</span> on awakening) experiencing primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span>. Each of these syndromes of idiopathic generalized <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> was well represented in this patient population.
</p>
<p>There was a statistically significant decrease from baseline in PGTC frequency in the levetiracetam-treated patients compared to the placebo-treated patients in Study 7 (see <a href="#t15">Table 15</a>).
</p>
<a name="t15"></a><table width="100%">
<caption><span>Table 15: Median Percent Reduction from Baseline in PGTC <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Frequency per Week in Study 7
</span></caption>
<col align="left" width="41.067%">
<col align="left" width="32.133%">
<col align="left" width="26.800%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">*</span>statistically significant versus placebo
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">Placebo<br>(N=84)
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">Levetiracetam<br>(N=78)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">Percentage reduction in PGTC <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency
</td>
<td class="Botrule Rrule" align="center" valign="middle">44.6%
</td>
<td class="Botrule Rrule" align="center" valign="middle">77.6%<span class="Sup">*</span>
</td>
</tr>
</tbody>
</table>
<p>The percentage of patients (y-axis) who achieved ≥50% reduction in weekly <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> rates from baseline in PGTC <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency over the entire randomized treatment period (titration + evaluation period) within the two treatment groups (x-axis) is presented in <a href="#fig6">Figure 6</a>.
</p>
<p><a name="fig6"></a><span class="Bold">Figure 6: Responder Rate (≥50% Reduction from Baseline) in PGTC <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Frequency per Week in Study 7</span></p>
<p><a name="f07"></a><img alt="Figure 6
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f00d8f59-c333-48ad-aca3-98a49bcd228e&amp;name=lev00-0008-07.jpg"></p>
<p><span class="Bold">*</span>statistically significant versus placebo
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s111"></a><a name="section-13"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s112"></a><a name="section-13.1"></a><p></p>
<h2>16.1 How Supplied
</h2>
<p class="First">Levetiracetam Injection is supplied as follows:
</p>
<table width="100%">
<col align="left" width="20.600%">
<col align="left" width="46.067%">
<col align="left" width="33.333%">
<tbody class="Headless">
<tr class="First">
<td align="justify" valign="top"><span class="Bold">NDC</span></td>
<td align="justify" valign="top"><span class="Bold">Levetiracetam Injection (100 mg per mL)</span></td>
<td align="justify" valign="top"><span class="Bold">Package Factor</span></td>
</tr>
<tr class="Last">
<td align="justify" valign="top">25021-780-05
</td>
<td align="justify" valign="top">500 mg per 5 mL Single-Dose Vial
</td>
<td align="justify" valign="top">10 vials per carton
</td>
</tr>
</tbody>
</table>
<p>Levetiracetam Injection is a clear, colorless, sterile solution.
</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="s113"></a><a name="section-13.2"></a><p></p>
<h2>16.2 Storage
</h2>
<p class="First">Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F). [See USP Controlled Room Temperature.]
</p>
<p>Discard unused portion.
</p>
<p><span class="Bold">Sterile, Nonpyrogenic, Preservative-free.</span></p>
<p><span class="Bold">The container closure is not made with natural rubber latex.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s114"></a><a name="section-14"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s115"></a><a name="section-14.1"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> and Ideation</span></p>
<p>Counsel patients, their caregivers, and/or families that antiepileptic drugs (AEDs), including levetiracetam, may increase the risk of suicidal thoughts and behavior and advise patients to be alert for the emergence or worsening of symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; unusual changes in mood or behavior; or suicidal thoughts, behavior, or thoughts about self-harm. Advise patients, their caregivers, and/or families to immediately report behaviors of concern to a healthcare provider.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s116"></a><a name="section-14.2"></a><p></p>
<p class="First"><span class="Underline">Psychiatric Reactions and Changes in Behavior</span></p>
<p>Advise patients and their caregivers that levetiracetam may cause changes in behavior (e.g., <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4327815" conceptname="Feeling angry">anger</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, and <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>) and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> symptoms.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s117"></a><a name="section-14.3"></a><p></p>
<p class="First"><span class="Underline">Effects on Driving or Operating Machinery</span></p>
<p>Inform patients that levetiracetam may cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>. Inform patients not to drive or operate machinery until they have gained sufficient experience on levetiracetam to gauge whether it adversely affects their ability to drive or operate machinery.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s118"></a><a name="section-14.4"></a><p></p>
<p class="First"><span class="Underline">Dermatological Adverse Reactions</span></p>
<p>Advise patients that serious dermatological adverse reactions have occurred in patients treated with levetiracetam and instruct them to call their physician immediately if a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> develops.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s119"></a><a name="section-14.5"></a><p></p>
<p class="First"><span class="Underline">Pregnancy</span></p>
<p>Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during levetiracetam therapy. Encourage patients to enroll in the North American Antiepileptic Drug (NAAED) pregnancy registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll free number 1-888-233-2334 [<span class="Italics">see Use In Specific Populations (<a href="#s53">8.1</a>)</span>].
</p>
<p>SAGENT™
</p>
<p>Mfd. for SAGENT Pharmaceuticals<br>Schaumburg, IL 60195 (USA)<br>Made in India<br>©2015 Sagent Pharmaceuticals, Inc.
</p>
<p>Revised: March 2015
</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s120"></a><a name="section-15"></a><p></p>
<p class="First">PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label
</p>
<p>NDC 25021-780-05
</p>
<p>Rx only
</p>
<p>Levetiracetam Injection
</p>
<p>500 mg per 5 mL
</p>
<p>(100 mg per mL)
</p>
<p>For IV Use
</p>
<p>Must Be Diluted Before Use
</p>
<p>5 mL Single-Dose Vial
</p>
<div class="Figure">
<a name="f08"></a><img alt="PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f00d8f59-c333-48ad-aca3-98a49bcd228e&amp;name=lev00-0008-08.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LEVETIRACETAM 		
					</strong><br><span class="contentTableReg">levetiracetam injection, solution, concentrate</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:25021-780</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Levetiracetam</strong> (Levetiracetam) </td>
<td class="formItem">Levetiracetam</td>
<td class="formItem">500 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>acetic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium acetate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:25021-780-05</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091627</td>
<td class="formItem">11/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sagent Pharmaceuticals
							(796852890)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>89a584da-64e9-484e-89d3-58431f5bcc7a</div>
<div>Set id: f00d8f59-c333-48ad-aca3-98a49bcd228e</div>
<div>Version: 8</div>
<div>Effective Time: 20150327</div>
</div>
</div> <div class="DistributorName">Sagent Pharmaceuticals</div></p>
</body></html>
